정신분열병에서 Quetiapine의 치료 효능과 안전성

Abstract

Atypical antipsychotics have an improved tolerability profile, and are less likely to cause debilitating extrapyram-idal symptoms (EPS) than are the conventional antipsychotics. Quetiapine, the fourth atypical antipsychotic, was marketed in Korea as well as in the United States and is also available in over 85 countries worldwide. The aim of this review is to describe the efficacy, safety, and tolerability of quetiapine in treating patients with schizophrenia. Based upon a review of published findings, quetiapine has shown efficacy in a broad symptom range and a good tolerability profile featuring placebo-level EPS and prolactin across the recommended dose range, and a favorable long-term weight profile. In addition, quetiapine has beneficial calming properties and successfully treats the symp-toms of aggression, hostility and anxiety that can accompany acute exacerbations of schizophrenia. In conclusion, quetiapine is well tolerated and clinically effective in the treatment of schizophrenia.